You are here

Our science / Clinical Trials / Find a Trial / NCT00655369

A Double-blind, Parallel Group, Placebo-Controlled Outpatient Trial of PD 00200390 in Adults With Nonrestorative Sleep

Back to Search Print Save as PDF Bookmark Trial

NCT00655369

Last updated on November 21, 2019
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Glendale, Arizona, 85306 United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Nonrestorative Sleep
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-64 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Awake unrestored or unrefreshed, associated with significant distress or impairment in
social, occupational, or other important areas of functioning during the daytime, for
at least 3 nights for the past 3 months prior to screening

- Self-report wake after sleep onset sleep onset

- PSG (Polysomnography) sleep criteria of wake after sleep onset persistent sleep

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- MAP (Multivariable Apnea Risk index) index > or = 0.5 at screening

- BMI = or > 32 kg/m2

- History or presence of breathing related disorders

- PSG findings consistent with and periodic limb movement disorder, narcolepsy or other
dyssomnia or parasomnia including apnea-hypopnea index > 10/hr; or period limb
movement with arousal index > 10/hr.

NCT00655369
Pfizer
Completed
A Double-blind, Parallel Group, Placebo-Controlled Outpatient Trial of PD 00200390 in Adults With Nonrestorative Sleep

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Advanced Search
Descriptive Information
Brief Title  ICMJE A Double-blind, Parallel Group, Placebo-Controlled Outpatient Trial of PD 00200390 in Adults With Nonrestorative Sleep
Official Title  ICMJE PD 0200390 Dose-Ranging Trial: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Outpatient Trial of PD 0200390 in Adults With Nonrestorative Sleep
Brief SummaryIn a Phase II trial in subjects with nonrestorative sleep, PD 0200390 demonstrated a positive treatment effect relative to placebo on the primary endpoint, the weekly version of the Restorative Sleep Questionnaire (RSQ-W). In this study, the dose-response relationship of varying doses of PD 0200390 using the Restorative Sleep Questionnaire (RSQ-W), will be explored in Nonrestorative Sleep subjects.
Detailed DescriptionNot Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Nonrestorative Sleep
Intervention  ICMJE
  • Drug: PD 0200390
    oral 15 mg daily dose, 3 capsules per dose during a six week treatment period.
  • Drug: PD 0200390
    oral 25 mg daily dose, 3 capsules per dose during a six week treatment period.
  • Drug: PD 0200390
    oral 35 mg daily dose, 3 capsules per dose during a six week treatment period.
  • Drug: PD 0200390
    oral 5 mg daily dose, 3 capsules per dose during a six week treatment period.
  • Drug: PD 0200390
    oral 50 mg daily dose, 3 capsules per dose during a six week treatment period.
  • Drug: Placebo
    oral placebo daily dose, 3 capsules per dose during a six week treatment period.
Study Arms  ICMJE
  • Experimental: 15 mg
    Intervention: Drug: PD 0200390
  • Experimental: 25 mg
    Intervention: Drug: PD 0200390
  • Experimental: 35 mg
    Intervention: Drug: PD 0200390
  • Experimental: 5 mg
    Intervention: Drug: PD 0200390
  • Experimental: 50 mg
    Intervention: Drug: PD 0200390
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo
Publications *Drake CL, Hays RD, Morlock R, Wang F, Shikiar R, Frank L, Downey R, Roth T. Development and evaluation of a measure to assess restorative sleep. J Clin Sleep Med. 2014 Jul 15;10(7):733-41, 741A-741E. doi: 10.5664/jcsm.3860.


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: January 20, 2009)		306
Original Estimated Enrollment  ICMJE
 (submitted: April 3, 2008)		300
Actual Study Completion Date  ICMJE December 2008
Actual Primary Completion DateDecember 2008   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Awake unrestored or unrefreshed, associated with significant distress or impairment in social, occupational, or other important areas of functioning during the daytime, for at least 3 nights for the past 3 months prior to screening
  • Self-report wake after sleep onset <45 mins for past 3 mos; self-report latency to sleep onset <20 mins for past 3 mos
  • PSG (Polysomnography) sleep criteria of wake after sleep onset < 45 mins; Latency to persistent sleep <20 mins.

Exclusion Criteria:

  • MAP (Multivariable Apnea Risk index) index > or = 0.5 at screening
  • BMI = or > 32 kg/m2
  • History or presence of breathing related disorders
  • PSG findings consistent with and periodic limb movement disorder, narcolepsy or other dyssomnia or parasomnia including apnea-hypopnea index > 10/hr; or period limb movement with arousal index > 10/hr.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 64 Years   (Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00655369
Other Study ID Numbers  ICMJE A4251033
Has Data Monitoring CommitteeNo
U.S. FDA-regulated ProductNot Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible PartyPfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS AccountPfizer
Verification DateJuly 2012

ICMJE     Data element required by the

International Committee of Medical Journal Editors and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now